Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Lee, Jung Pyo ^a,b,c   Yang, Seung Hee ^b,c   Lee, Hee Yoon ^d   Kim, Bora ^c   Cho, Joo Youn ^c   Paik, Jin Ho ^c   Oh, Yun Jung ^c   Kim, Dong Ki ^b,c   Lim, Chun Soo ^a,b,c   Kim, Yon Su ^b,c  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

12 (3 ADAMANTAN 1 YLUREIDO)DODECANOIC ACID; CYTOKINE; DIHYDROXYOCTADEC 12 ENOIC ACID; ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; EPOXYOCTADECENOIC ACID; SOLUBLE EPOXIDE HYDROLASE; UNCLASSIFIED DRUG; 12-(3-ADAMANTAN-1-YLUREIDO)DODECANOIC ACID; ADAMANTANE; DRUG DERIVATIVE; LAURIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL MIGRATION; CONCENTRATION RESPONSE; DISEASE SEVERITY; DOWN REGULATION; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME REGULATION; ENZYME REPRESSION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATORY CELL; KIDNEY DYSFUNCTION; KIDNEY ISCHEMIA; KIDNEY TUBULE NECROSIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY; UPREGULATION; ANGIOGENESIS; ANIMAL; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HOSPITALIZATION; KIDNEY; MALE; METABOLISM;

MUS;

ADAMANTANE; ANIMALS; CELL MOVEMENT; CYTOKINES; ENDOTHELIAL CELLS; EPOXIDE HYDROLASES; KIDNEY; LAURIC ACIDS; MALE; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; REPERFUSION INJURY; SEVERITY OF ILLNESS INDEX;

EID: 84861011092     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037075     Document Type: Article

References (47)

1. Santos WJ, Zanetta DM, Pires AC, Lobo SM, Lima EQ, et al. (2006) Patients with ischaemic, mixed and nephrotoxic acute tubular necrosis in the intensive care unit-a homogeneous population? Crit Care 10: R68.
2. Levy EM, Viscoli CM, Horwitz RI, (1996) The effect of acute renal failure on mortality. A cohort analysis. JAMA 275: 1489-1494.
3. Yang SH, Lee JP, Jang HR, Cha RH, Han SS, et al. (2011) Sulfatide-Reactive Natural Killer T Cells Abrogate Ischemia-Reperfusion Injury. J Am Soc Nephrol 22: 1305-1314.
4. Jang HR, Ko GJ, Wasowska BA, Rabb H, (2009) The interaction between ischemia-reperfusion and immune responses in the kidney. J Mol Med 87: 859-864.
5. Campbell WB, Gebremedhin D, Pratt PF, Harder DR, (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78: 415-423.
6. Zeldin DC, (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276: 36059-36062.
7. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, et al. (1999) Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-497.
8. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR, (1996) Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7: 2364-2370.
9. Imig JD, (2005) Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289: F496-503.
10. Node K, Huo Y, Ruan X, Yang B, Spiecker M, et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279.
11. Heizer ML, McKinney JS, Ellis EF, (1991) 14,15-Epoxyeicosatrienoic acid inhibits platelet aggregation in mouse cerebral arterioles. Stroke 22: 1389-1393.
12. Fang X, Weintraub NL, McCaw RB, Hu S, Harmon SD, et al. (2004) Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol 287: H2412-2420.
13. Lee JP, Yang SH, Kim DK, Lee H, Kim B, et al. (2011) In-vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathy. Am J Physiol Renal Physiol 300: F1283-1290.
14. Lee SH, Lee J, Cha R, Park MH, Ha JW, et al. (2008) Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation. Transplant Proc 40: 1353-1356.
15. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, et al. (2005) An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 46: 842-848.
16. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, et al. (2007) Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 27: 1931-1940.
17. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, et al. (2006) Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99: 442-450.
18. Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ, (2007) Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat 82: 50-59.
19. Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, et al. (2008) Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol 295: H2128-2134.
20. McPherson C, (1980) Regulation of animal care and research? NIH's opinion. J Anim Sci 51: 492-496.
21. Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, et al. (2007) Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorg Med Chem 15: 312-323.
22. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, et al. (2005) Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45: 759-765.
23. Jang HR, Gandolfo MT, Ko GJ, Satpute S, Racusen L, et al. (2009) Early exposure to germs modifies kidney damage and inflammation after experimental ischemia-reperfusion injury. Am J Physiol Renal Physiol 297: F1457-1465.
24. Newman JW, Watanabe T, Hammock BD, (2002) The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res 43: 1563-1578.
25. Donnahoo KK, Meng X, Ayala A, Cain MP, Harken AH, et al. (1999) Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol 277: R922-929.
26. Haq M, Norman J, Saba SR, Ramirez G, Rabb H, (1998) Role of IL-1 in renal ischemic reperfusion injury. J Am Soc Nephrol 9: 614-619.
27. Daemen MA, de Vries B, van't Veer C, Wolfs TG, Buurman WA, (2001) Apoptosis and chemokine induction after renal ischemia-reperfusion. Transplantation 71: 1007-1011.
28. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, et al. (2001) Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 60: 2118-2128.
29. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, et al. (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A 102: 9772-9777.
30. Basile DP, Donohoe D, Roethe K, Osborn JL, (2001) Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol 281: F887-899.
31. Chen JK, Capdevila J, Harris RC, (2002) Heparin-binding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells. Proc Natl Acad Sci U S A 99: 6029-6034.
32. Michaelis UR, Fisslthaler B, Medhora M, Harder D, Fleming I, et al. (2003) Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J 17: 770-772.
33. Haase VH, (2006) Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 291: F271-281.
34. Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, et al. (2002) Expression of hypoxia-inducible factor-1alpha and-2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13: 1721-1732.
35. Nangaku M, Eckardt KU, (2007) Hypoxia and the HIF system in kidney disease. J Mol Med 85: 1325-1330.
36. Basile DP, Fredrich K, Chelladurai B, Leonard EC, Parrish AR, (2008) Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am J Physiol Renal Physiol 294: F928-936.
37. Liu M, Alkayed NJ, (2005) Hypoxic preconditioning and tolerance via hypoxia inducible factor (HIF) 1alpha-linked induction of P450 2C11 epoxygenase in astrocytes. J Cereb Blood Flow Metab 25: 939-948.
38. Cheranov SY, Karpurapu M, Wang D, Zhang B, Venema RC, et al. (2008) An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. Blood 111: 5581-5591.
39. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, et al. (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275: 40504-40510.
40. Xu D, Li N, He Y, Timofeyev V, Lu L, et al. (2006) Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 103: 18733-18738.
41. Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, et al. (2004) Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109: 335-339.
42. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, et al. (2005) The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 14: 2829-2837.
43. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, et al. (2006) Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15: 1640-1649.
44. Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, et al. (2007) Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J Neurosci 27: 4642-4649.
45. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, et al. (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 15: 1244-1253.
46. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, et al. (2005) An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46: 975-981.
47. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, et al. (2009) Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 297: F740-748.